Emerging Clinical and Biological Developments
The move toward personalized medicine is one of the most significant Immune Thrombocytopenia Market trends observed this year. Physicians are increasingly using biomarkers to predict which patients will respond best to specific treatments, such as Rituximab or Thrombopoietin Receptor Agonists (TPO-RAs). This "precision hematology" approach reduces the trial-and-error period, sparing patients...
0 Commentaires 0 Parts 199 Vue 0 Aperçu